Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adult neural stem cell therapy - Microbot Medical

Drug Profile

Adult neural stem cell therapy - Microbot Medical

Alternative Names: hCNS-SC; HuCNS-SC; HuCNS-SC cells; Neurodegenerative disorders stem cell therapy - Microbot Medical

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator StemCells
  • Developer Microbot Medical; Oregon Health & Science University; StemCells; University of California at Irvine
  • Class Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Myelin protein stimulants; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Retinal disorders

Highest Development Phases

  • Phase II Spinal cord injuries
  • Suspended Alzheimer's disease; Dry age-related macular degeneration
  • No development reported Pelizaeus-Merzbacher disease; Stroke
  • Discontinued Neuronal ceroid lipofuscinosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pelizaeus-Merzbacher-disease in USA (Intracerebral, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)
  • 28 Nov 2016 StemCells has been acquired and merged into Microbot Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top